These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Clinical relevance of skin barrier changes associated with the use of oral isotretinoin: the importance of barrier repair therapy in patient management. Del Rosso JQ J Drugs Dermatol; 2013 Jun; 12(6):626-31. PubMed ID: 23839177 [TBL] [Abstract][Full Text] [Related]
26. Use of systemic agents in the treatment of acne vulgaris. Johnson BA; Nunley JR Am Fam Physician; 2000 Oct; 62(8):1823-30, 1835-6. PubMed ID: 11057839 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of fixed low-dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in moderately severe acne vulgaris. Sardana K; Garg VK; Sehgal VN; Mahajan S; Bhushan P J Eur Acad Dermatol Venereol; 2009 May; 23(5):556-60. PubMed ID: 19143903 [TBL] [Abstract][Full Text] [Related]
28. On isotretinoin dosing, adverse effects, and efficacy. Berk DR Australas J Dermatol; 2011 May; 52(2):147-8; author reply 148. PubMed ID: 21605103 [No Abstract] [Full Text] [Related]
29. Oral Isotretinoin: New Developments Relevant to Clinical Practice. Tan J; Boyal S; Desai K; Knezevic S Dermatol Clin; 2016 Apr; 34(2):175-84. PubMed ID: 27015777 [TBL] [Abstract][Full Text] [Related]
30. Vitamin D levels in acne vulgaris patients treated with oral isotretinoin. El-Hamd MA; El Taieb MA; Ibrahim HM; Aly SS J Cosmet Dermatol; 2019 Feb; 18(1):16-20. PubMed ID: 29460332 [TBL] [Abstract][Full Text] [Related]
31. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Layton AM; Dréno B; Gollnick H; Mobaken H; Shear N Br J Dermatol; 2009 Jan; 160(1):217-8; author reply 218-9. PubMed ID: 19067687 [No Abstract] [Full Text] [Related]
32. [Acne in the newborn and infants]. Plantin P; Ann Dermatol Venereol; 2008; 135(6-7):518-20; quiz 517, 521. PubMed ID: 18598809 [No Abstract] [Full Text] [Related]
33. Enhancing Bioavailability: Advances in Oral Isotretinoin Formulations. Michael K; Tan J Skin Therapy Lett; 2024 Sep; 29(5):10-12. PubMed ID: 39353206 [TBL] [Abstract][Full Text] [Related]
34. Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne. Webster GF; Leyden JJ; Gross JA J Drugs Dermatol; 2014 Jun; 13(6):665-70. PubMed ID: 24918555 [TBL] [Abstract][Full Text] [Related]
36. Isotretinoin-induced skin fragility in a teenaged athlete: a case report. Pavlis MB; Lieblich L Cutis; 2013 Jul; 92(1):33-4. PubMed ID: 23961523 [TBL] [Abstract][Full Text] [Related]
37. Systemic therapy for acne vulgaris. Layton AM Hosp Med; 2004 Feb; 65(2):80-5. PubMed ID: 14997773 [TBL] [Abstract][Full Text] [Related]
38. Adverse effects of isotretinoin therapy for acne vulgaris. Lamb SR; Oakley AM N Z Med J; 2001 Sep; 114(1139):414. PubMed ID: 11665936 [No Abstract] [Full Text] [Related]
39. Effects of oral isotretinoin on serum folic acid levels. Javanbakht AM; Pour HM; Tarrahic MJ J Drugs Dermatol; 2012 Sep; 11(9):e23-4. PubMed ID: 23135667 [TBL] [Abstract][Full Text] [Related]
40. Laboratory Monitoring During Isotretinoin Therapy for Acne: A Systematic Review and Meta-analysis. Lee YH; Scharnitz TP; Muscat J; Chen A; Gupta-Elera G; Kirby JS JAMA Dermatol; 2016 Jan; 152(1):35-44. PubMed ID: 26630323 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]